Neurology
Paraneoplastic encephalitis: clinically based approach on diagnosis and management.
16 Aug, 2022 | 13:19h | UTC
M-A | Effect of regional anesthesia on postoperative delirium.
16 Aug, 2022 | 13:08h | UTC
Review | Long COVID headache.
15 Aug, 2022 | 12:25h | UTCLong COVID headache – The Journal of Headache and Pain
Commentary on Twitter
#Headache is among the most frequent symptoms persisting or newly developing after #coronavirus disease 2019 (COVID-19) as part of the so-called long #COVID syndrome. Learn more: https://t.co/v1V2jZBluq pic.twitter.com/X6eAgaOaBF
— European Headache Federation (@EHF_Official) August 4, 2022
Under a http://creativecommons.org/licenses/by/4.0/ license
RCT | A small study evaluated the safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral hemorrhage.
15 Aug, 2022 | 12:01h | UTCSafety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Neurology (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Small study that is not powered to answer this question but raises an interesting ❓ nonetheless: should we use prophylactic antiseizure 💊in #ich? Most recently updated guidelines recommend against this practice. https://t.co/NH45OCtzvv
— Richard Choi, DO, FNCS (@rkchoi) August 11, 2022
Cohort Study | Analysis of clinical features, diagnostic tests, and biomarkers in patients with suspected Creutzfeldt-Jakob Disease.
15 Aug, 2022 | 11:47h | UTC
Commentary on Twitter
In patients with suspected Creutzfeldt-Jakob disease, CSF RT-QuIC, CSF T-tau, and stereotyped MRI anomalies were associated with diagnosis; myoclonus, stereotyped EEG anomalies, and CSF protein 14-3-3 were less helpful. #CohortStudy https://t.co/w3iaHMj3co
— JAMA Network Open (@JAMANetworkOpen) August 3, 2022
International consensus recommendations for management of New Onset Refractory Status Epilepticus (NORSE) including Febrile Infection-Related Epilepsy Syndrome (FIRES).
12 Aug, 2022 | 14:50h | UTC
Podcast | Multiple Sclerosis pearls for the general practitioner.
12 Aug, 2022 | 14:21h | UTC#344 Multiple Sclerosis with Dr. Annette Okai – The Curbsiders
RCT | Among patients with symptomatic intracranial stenosis, the addition of stenting to medical therapy is not better at reducing the risk of stroke or death compared to medical therapy alone.
10 Aug, 2022 | 15:36h | UTCEditorial: Therapeutic Strategies for Intracranial Atherosclerosis – JAMA (free for a limited period)
Commentary: Stenting Hits Another Wall in Intracranial Stenosis Stroke – MedPage Today (free registration required)
Commentary on Twitter
Findings of this #RandomizedClinicalTrial do not support the addition of percutaneous transluminal angioplasty and stenting to medical therapy for the treatment of patients with symptomatic severe intracranial atherosclerotic stenosis. https://t.co/X9qi3WQ0JC pic.twitter.com/rH6aDo4GjV
— JAMA (@JAMA_current) August 9, 2022
RCT | In patients with large vessel occlusion stroke, intravenous Tirofiban before endovascular thrombectomy does not improve functional outcomes.
10 Aug, 2022 | 15:34h | UTCEffect of Intravenous Tirofiban vs Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The RESCUE BT Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract
Commentary: RESCUE BT: IV Tirofiban No Help During Stroke Thrombectomy – TCTMD
Cohort Study | Association of younger vs. older ages with changes in incidence of stroke and other vascular events, 2002-2018.
10 Aug, 2022 | 15:30h | UTCAssociation of Younger vs Older Ages With Changes in Incidence of Stroke and Other Vascular Events, 2002-2018 – JAMA (free for a limited period)
See also: Diverging Temporal Trends in Stroke Incidence in Younger vs Older People: A Systematic Review and Meta-analysis – JAMA Neurology (free for a limited period)
Commentaries on Twitter
Data from Oxford area in @JAMA_current show worrisome incr. in stroke rate in adults <55 yrs comparing two time periods. 67% incr seen in younger adults, 15% decr in older adults. Need further study of why young stroke rates are on the rise#MYStrokeCenterhttps://t.co/MG4MgUGAA4
— Seemant Chaturvedi (@ChaturvediNeuro) August 9, 2022
The consistently divergent temporal trend in stroke incidence at younger vs older ages highlights the urgent need to better understand etiology and prevention of stroke at younger ages. https://t.co/phhRcpWwRw
— JAMA Neurology (@JAMANeuro) August 9, 2022
Systematic Review | Patch angioplasty versus primary closure for carotid endarterectomy.
10 Aug, 2022 | 12:30h | UTCPatch angioplasty versus primary closure for carotid endarterectomy – Cochrane Library
Summary: Patch angioplasty versus primary closure for carotid endarterectomy – Cochrane Library
Multiple Sclerosis in children: differential diagnosis, prognosis, and disease-modifying treatment
10 Aug, 2022 | 12:18h | UTC
M-A | Global prevalence and incidence of tinnitus.
9 Aug, 2022 | 12:57h | UTCGlobal Prevalence and Incidence of Tinnitus: A Systematic Review and Meta-analysis – JAMA Neurology (free for a limited period)
Commentary: Review: Global Pooled Prevalence of Tinnitus 14.4 Percent – HealthDay
Commentary on Twitter
The global burden of #tinnitus is large, similar to #migraine and pain, and the lack of effective treatment options justifies a major investment in research in this area. https://t.co/9uVJmnYh9c
— JAMA Neurology (@JAMANeuro) August 8, 2022
Review | Role of imaging in CNS infections.
9 Aug, 2022 | 12:26h | UTCRole of imaging in CNS infections – Indian Journal of Pathology & Microbiology
Two randomized trials found monoclonal antibodies are no better than placebo for Parkinson’s Disease.
8 Aug, 2022 | 11:53h | UTCStudy 1: Trial of Cinpanemab in Early Parkinson’s Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Study 2: Trial of Prasinezumab in Early-Stage Parkinson’s Diseas – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Monoclonal Antibodies No Better Than Placebo for Early Parkinson Disease – HealthDay
Systematic Review | Action observation for upper limb rehabilitation after stroke.
8 Aug, 2022 | 11:26h | UTCAction observation for upper limb rehabilitation after stroke – Cochrane Library
Retrospective Cohort Study | Retrospective evaluation of ophthalmological and neurological outcomes for infants born before 24 weeks gestational age.
8 Aug, 2022 | 11:24h | UTC
Review | Adults with intellectual disabilities and mental health disorders in primary care.
5 Aug, 2022 | 14:24h | UTC
Enhancing primary stroke prevention: a combination approach.
4 Aug, 2022 | 14:42h | UTCEnhancing primary stroke prevention: a combination approach – The Lancet Public Health
Commentary on Twitter
Primary #stroke #prevention strategies target behavioural and pharmacological approaches. Also need to manage structural factors that support or hinder prevention actions and behaviours. @StrokeImperial @Simzy_x @Tsering_ @SomaBanerjee73 @CFCFoundation
https://t.co/vyyhhfeg7Y pic.twitter.com/kqwF9DROG2— Joseph Kwan, MD 🇬🇧 (@drjkwan) July 31, 2022
Under a Creative Commons Attribution (CC BY 4.0) license
RCT | Transcranial direct current stimulation vs. sham for the treatment of inattention in adults with attention-deficit/hyperactivity disorder.
4 Aug, 2022 | 13:50h | UTCTranscranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults With Attention-Deficit/Hyperactivity Disorder: The TUNED Randomized Clinical Trial – JAMA Psychiatry (free for a limited period)
See also: Visual Abstract
RCT | Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis.
4 Aug, 2022 | 13:28h | UTCComparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial – The Lancet Neurology (link to abstract – $ for full-text)
Commentary: Less Frequent Dosing With MS Drug Safe With No Loss of Efficacy – Medscape (free registration required)
RCT | Effect of graded sensorimotor retraining on pain intensity in patients with chronic low back pain.
3 Aug, 2022 | 14:08h | UTCEffect of Graded Sensorimotor Retraining on Pain Intensity in Patients With Chronic Low Back Pain: A Randomized Clinical Trial – JAMA (free for a limited period)
News release: An effective new treatment for chronic back pain targets the nervous system – University of New South Wales
Commentary on Twitter
A graded sensorimotor retraining intervention, compared with a sham procedure and attention control, resulted in a statistically significant improvement in pain intensity at 18 weeks. https://t.co/MXO89JeOSe pic.twitter.com/0A865RWW85
— JAMA (@JAMA_current) August 2, 2022
Retrospective Cohort Study | Syncope and the risk of subsequent motor vehicle crash.
2 Aug, 2022 | 12:33h | UTCSyncope and the Risk of Subsequent Motor Vehicle Crash: A Population-Based Retrospective Cohort Study – JAMA Internal Medicine (free for a limited period)
Editorial: Driving Safety After an Acute Illness—This Is Our Lane – JAMA Internal Medicine (free for a limited period)
Commentary on Twitter
"I fainted…am I safe to drive?" Study found that 9,223 drivers with an ED visit for syncope had subsequent crash risks no different than controls, suggesting more stringent driving restrictions might not be justified. https://t.co/T0GUJ63Nci
— JAMA Internal Medicine (@JAMAInternalMed) August 1, 2022
Cohort Study | Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment.
2 Aug, 2022 | 12:26h | UTCAssociation of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment – JAMA Neurology (link to abstract – $ for full-text)
Commentary on Twitter
Study found that Aβ and tau PET positivity in cognitively unimpaired individuals was associated with near-term progression to mild cognitive impairment and, among those who do not show such categorical change, longitudinal cognitive decline. https://t.co/sKpST7e4Nh
— JAMA Neurology (@JAMANeuro) July 30, 2022
Saudi consensus recommendations on the management of multiple sclerosis in children and adolescents.
2 Aug, 2022 | 12:13h | UTC